Tumor Prognosis via eIF Expression Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack reliable and comprehensive tumor markers for prognosis and differential diagnosis of tumors, particularly in lymphoma and hepatocellular carcinoma, as existing studies have not fully analyzed the relationship between eukaryotic initiation factors (eIFs) and patient outcomes.
Innovation Solution
Determining the levels of specific eIFs such as eIF2AK4, eIF2B4, eIF2C 3, eIF2d, eIF-2α, eIF2S2, eIF3b, eIF3c, eIF3d, eIF3f, eIF3g, eIF31, eIF-4B, 4E-BP1, eIF-4G1, eIF-5A, eIF2AK3/HsPEK, eIF-4E3, eIF-5, eIF1AD, eIF1AX, eIF1AY, eIF-2A, eIF2B5, eIF3j, and eIF4A2 in patient samples and comparing them to reference levels to provide a prognosis for tumor diagnosis and differential diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If comprehensive studies analyzing the whole range of eIFs are conducted to identify reliable tumor markers, then the reliability of tumor prognosis and diagnosis is improved, but the complexity and time required for research and analysis increases
Solution Approach 1:
The comprehensive analysis of eIFs is segmented by focusing on specific subsets of eIFs (eIF2AK4, eIF2B4, eIF2C3, eIF2d, eIF-2α, eIF2S2, eIF3b, eIF3c, eIF3d, eIF3f, eIF3g, eIF31, eIF-4B, 4E-BP1, eIF-4G1, eIF-5A, eIF2AK3/HsPEK, eIF-4E3, eIF-5, eIF1AD, eIF1AX, eIF1AY, eIF-2A, eIF2B5, eIF3j, and eIF4A2) that have been identified as most relevant for lymphoma and hepatocellular carcinoma prognosis. This segmentation reduces the complexity while maintaining reliability.
Solution Approach 2:
Preliminary comprehensive studies have already been conducted to identify the most relevant eIFs for tumor prognosis. These preliminary actions have established the specific eIF markers and their reference levels, which can now be directly applied in clinical practice without repeating the entire research process, thus reducing current complexity while maintaining reliability.
2Measurement precision
If the levels of multiple eIFs are determined and compared to reference levels to provide prognosis, then the accuracy of differential diagnosis between specific tumor entities is improved, but the quantity of measurements and time required increases
Solution Approach 1:
The measurement process is segmented by focusing on specific eIF markers that have been pre-identified as most relevant for differential diagnosis. Rather than measuring all possible eIFs, the method segments the analysis to specific markers (e.g., eIF2AK4 for general prognosis, specific combinations for lymphoma vs. hepatocellular carcinoma differentiation), reducing the quantity of measurements while maintaining diagnostic accuracy.
Solution Approach 2:
Preliminary research has already identified the most relevant eIF markers and established reference levels for different tumor types. This preliminary action allows clinicians to directly apply these pre-established markers and reference levels without conducting new comprehensive measurements, thus reducing the quantity of measurements required while maintaining high diagnostic accuracy.
3Reliability
If eIF expression levels are analyzed to provide prognosis for lymphoma and hepatocellular carcinoma, then the usefulness of tumor markers is improved, but the difficulty of detecting and measuring eIFs increases
Solution Approach 1:
The eIF markers identified (eIF2AK4, eIF2B4, eIF2C3, eIF2d, eIF-2α, eIF2S2, eIF3b, eIF3c, eIF3d, eIF3f, eIF3g, eIF31, eIF-4B, 4E-BP1, eIF-4G1, eIF-5A, eIF2AK3/HsPEK, eIF-4E3, eIF-5, eIF1AD, eIF1AX, eIF1AY, eIF-2A, eIF2B5, eIF3j, and eIF4A2) serve multiple functions: they can be used for general prognosis, differential diagnosis between lymphoma and hepatocellular carcinoma, and monitoring treatment response. This multi-functionality increases usefulness while the standardized measurement protocols reduce difficulty.
Solution Approach 2:
Preliminary studies have already optimized the detection and measurement protocols for these specific eIF markers. The reference levels have been pre-established, and the most reliable measurement approaches have been identified, reducing the difficulty of detection and measurement in clinical practice while maintaining high reliability of the tumor markers.
Data Source
Figure 1
Figure 1
Figure 2
AI summary
The present invention is in the field of tumor prognosis and relates to a method of providing a prognosis to an individual suffering from a tumor. Further, the present invention relates to a method of diagnosing a hepatocellular carcinoma (HCC) in an individual, a method of diagnosing a hepatitis C virus (HCV) infectionin an individual, a method of diagnosing a hepatitis B virus (HBV) infection in an individual, and a method of diagnosing a viral induced hepatocellular carcinoma in an individual. Furthermore, the present invention relates to a method of differentiating between at least two conditions in an individual, wherein the at least two conditions are selected from the group consisting of a hepatocellular carcinoma (HCC), hepatitis C virus (HCV) infection, hepatitis B virus (HBV) infection, and a viral induced hepatocellular carcinoma (HCC).In addition, the present invention relates to a method for diagnosing a lymphoma in an individual. More- over, the present invention relates to a kit for conducting the above mentioned methods.